Document is current
Any future updates will be listed below
-
Authors
,
Arabi, Yaseen M. http://orcid.org/0000-0001-5735-6241
Asiri, Ayed Y.
Assiri, Abdullah M.
Aziz Jokhdar, Hani A.
Alothman, Adel
Balkhy, Hanan H.
AlJohani, Sameera
Al Harbi, Shmeylan
Kojan, Suleiman
Al Jeraisy, Majed
Deeb, Ahmad M. http://orcid.org/0000-0002-3680-7338
Memish, Ziad A.
Ghazal, Sameeh
Al Faraj, Sarah
Al-Hameed, Fahad http://orcid.org/0000-0003-0231-871X
AlSaedi, Asim
Mandourah, Yasser
Al Mekhlafi, Ghaleb A.
Sherbeeni, Nisreen Murad
Elzein, Fatehi Elnour
Almotairi, Abdullah
Al Bshabshe, Ali
Kharaba, Ayman
Jose, Jesna
Al Harthy, Abdulrahman
Al Sulaiman, Mohammed
Mady, Ahmed
Fowler, Robert A.
Hayden, Frederick G.
Al-Dawood, Abdulaziz
Abdelzaher, Mohamed
Bajhmom, Wail
Hussein, Mohamed A.
-
Funding
Funding for this research was provided by:
King Abdullah International Medical Research Center (RC15/142/R)
- License Information
-
More Information
Article History
Received: 9 December 2018
Accepted: 24 October 2019
First Online: 3 January 2020
Ethics approval and consent to participate
: The MIRACLE study is approved by the Scientific Committee and the Institutional Review Board at the National Guard Health Affairs, Riyadh, Saudi Arabia (RC15/142) and all participating sites and registered at the Saudi Food and Drug Authority (SFDA), Riyadh, Saudi Arabia. Patients who meet the eligibility criteria or substitute decision-makers (for patients lacking decision-making capacity) of eligible patients will be approached to obtain informed consent for enrollment.
: Not applicable.
: The authors declare that they have no competing interests. YA and FGH are unpaid consultants on antivirals active for MERS for Gilead Sciences, SAB Biotherapeutics, and Regeneron.
